<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31518073</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Serum neurofilament heavy chains as early marker of motor neuron degeneration.</ArticleTitle><Pagination><StartPage>1971</StartPage><EndPage>1979</EndPage><MedlinePgn>1971-1979</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.50890</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To determine whether serum phosphorylated neurofilament heavy chain (pNfH) levels are elevated before patients were diagnosed with sporadic or familial ALS, and what the prognostic value of these prediagnostic pNfH levels is.</AbstractText><AbstractText Label="METHODS">pNfH was measured via ELISA in leftovers of serum drawn for routine purposes before the time of diagnosis. These prediagnostic samples were retrieved from the biobank of the University Hospitals Leuven for 95 patients who in follow-up received a diagnosis of ALS. Additionally, 35 patients with mild cognitive impairment (MCI) and 85 healthy controls (HC) were included in this retrospective study.</AbstractText><AbstractText Label="RESULTS">The median disease duration (range) from onset to prediagnostic sampling and from onset to diagnosis was 6.5 (-71.9-36.1) and 9.9 (2.0-40.7) months, respectively. Fifty-eight percent of the prediagnostic samples had serum pNfH levels above the 95th percentile of pNfH levels measured in HC. Serum pNfH levels (median (range)) were elevated up to 18&#xa0;months before the diagnosis of ALS (91&#xa0;pg/mL (6-342&#xa0;pg/mL)) in comparison with HC (30&#xa0;pg/mL (6-146&#xa0;pg/mL); P&#xa0;=&#xa0;0.05), and increased during the prediagnostic stage, which was not observed in patients with MCI. Furthermore, prediagnostic pNfH levels were a univariate predictor of survival in ALS (hazard ratio (95% CI): 2.16 (1.20-3.87); P&#xa0;=&#xa0;0.01).</AbstractText><AbstractText Label="INTERPRETATION">Our findings demonstrate that serum pNfH is elevated well before the time of diagnosis in mainly sporadic ALS patients. These results encourage to prospectively explore if pNfH has an added value to shorten the diagnostic delay in ALS.</AbstractText><CopyrightInformation>&#xa9; 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Schaepdryver</LastName><ForeName>Maxim</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2480-863X</Identifier><AffiliationInfo><Affiliation>Laboratory for Molecular Neurobiomarker Research, Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goossens</LastName><ForeName>Janne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Neurobiomarker Research, Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Meyer</LastName><ForeName>Steffi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Neurobiomarker Research, Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeromin</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Iron Horse Diagnostics, Inc, Scottsdale, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masrori</LastName><ForeName>Pegah</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Neurobiology, Center for Brain &amp; Disease Research, VIB, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Experimental Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brix</LastName><ForeName>Britta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Euroimmun AG, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claeys</LastName><ForeName>Kristl G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Laboratory for Muscle diseases and Neuropathies, Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaeverbeke</LastName><ForeName>Jolien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamczuk</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Neurobiology, Center for Brain &amp; Disease Research, VIB, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Experimental Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poesen</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Neurobiomarker Research, Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>start-up grant of the Group of Biomedical Sciences KU Leuven</Agency><Country>International</Country></Grant><Grant><Agency>Clinical Research fund of the University Hospitals Leuven</Agency><Country>International</Country></Grant><Grant><Agency>the Flemish Fund for Scientific Research (FWO, Fonds voor Wetenschappelijk Onderzoek Flanders, Belgium)</Agency><Country>International</Country></Grant><Grant><Agency>the Belgian ALS Liga</Agency><Country>International</Country></Grant><Grant><GrantID>11E6319N</GrantID><Agency>PhD Fellowship of the Research Foundation - Flanders</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018070" MajorTopicYN="N">Biological Specimen Banks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>M.D.S., J.G., S.D.M., P.M., J.S., K.A., K.G.C., R.V., and P.V.D. have nothing to report. K.P. received&#xa0;ELISA kits that&#xa0;were sponsored by Euroimmun AG (L&#xfc;beck, Germany). B.B. receives personal fees as a full time employee of Euroimmun AG (L&#xfc;beck, Germany). A.J. is a paid employee and stock holder of Iron Horse Diagnostics, Inc. (Scottsdale, AZ, USA).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31518073</ArticleId><ArticleId IdType="pmc">PMC6801162</ArticleId><ArticleId IdType="doi">10.1002/acn3.50890</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Turner MR, Wuu J. Defining pre&#x2010;symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler. Frontotemporal Degener. 2019;20:303&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6613999</ArticleId><ArticleId IdType="pubmed">30892087</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology 2012;79:1732&#x2013;1739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468777</ArticleId><ArticleId IdType="pubmed">23071166</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chi&#xf2; A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 2018;17:94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Kiernan MC. Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol 2006;117:1458&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pubmed">16759905</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal A, Nicholson G. Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation. J Neurol Neurosurg Psychiatry 2002;73:199&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1737965</ArticleId><ArticleId IdType="pubmed">12122184</ArticleId></ArticleIdList></Reference><Reference><Citation>Escorcio&#x2010;Bezerra ML, Abrahao A, Nunes KF, et al. Motor unit number index and neurophysiological index as candidate biomarkers of presymptomatic motor neuron loss in amyotrophic lateral sclerosis. Muscle Nerve 2018;58:204&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">29381812</ArticleId></ArticleIdList></Reference><Reference><Citation>Walhout R, Schmidt R, Westeneng H&#x2010;J, et al. Brain morphologic changes in asymptomatic C9orf72 repeat expansion carriers. Neurology 2015;85:1780&#x2013;1788.</Citation><ArticleIdList><ArticleId IdType="pubmed">26497991</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Sias AC, Mandelli ML, et al. Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. NeuroImage Clin 2017;14:286&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349617</ArticleId><ArticleId IdType="pubmed">28337409</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M, Jeromin A, Gille B, et al. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2018;89:367&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">29054919</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, De Schaepdryver M, Stubendorff B, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 2017;88:2302&#x2013;2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2016;87:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K, Yang C, Crook J, et al. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF&#x2010;H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF&#x2010;H as a potential ALS biomarker. J Neurochem 2009;111:1182&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">19765193</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan KB, Glass JD, Crook JE, et al. Phosphorylated neurofilament heavy subunit (pNF&#x2010;H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013;84:467&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">23117489</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, Oeckl P, Huss A, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol 2016;79:152&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">26528863</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, et al. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol 2018;84:130&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaeverbeke J, Gille B, Adamczuk K, et al. Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults. J Neurochem 2019;149:139&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">30720873</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H&#x2010;J, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 2018;17:423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D&#x2010;W, Ren H, Jeromin A, et al. Diagnostic Performance of Neurofilaments in Chinese Patients With Amyotrophic Lateral Sclerosis: A Prospective Study. Front Neurol 2018;9:726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6121092</ArticleId><ArticleId IdType="pubmed">30210445</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 2018;90:e22&#x2013;e30.</Citation><ArticleIdList><ArticleId IdType="pubmed">29212830</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>